Complete revascularization in acute myocardial infarction. 1 culprit lesion , then all the others

Original title: Randomized Trial of Preventive Angioplasty in Myocardial Infarction (PRAMI trial). Referencia: David S. Wald et al. N Engl J Med 2013.DOI: 10.1056/NEJMoa1305520.

Patients developing ST segment elevation myocardial infarction are effectively treated with primary angioplasty to responsible artery . It is unclear whether revascularized other significant lesions in other non culprit vessels  will prevent future events and in fact,  guides advise against it except when we are in the context of shock. The aim of this single-blind randomized trial was to evaluate whether practice preventive angioplasty in other injuries as part of primary angioplasty over the responsible artery may decrease the composite of cardiac death , myocardial infarction or refractory angina.

Between 2008 and 2013, 465 patients suffering ST segment elevation myocardial infarction were successfully treated for the responsible artery and that also had other lesions ≥ 50 % possibility of revascularization added for hemodynamic stability ( we excluded patients with left main coronary artery injury, chronic total occlusions and cardiogenic shock ) . Once primary angioplasty was completed we randomized remaining lesions to immediate preventive angioplasty  or terminate the procedure. Angioplasty in stages was discouraged and the only reason to revascularize non culprit injuries in the control branch was refractory angina with demonstrated ischemia. On January 24th, 2013 the trial was stopped early for the recommendation of the safety committee  given the significant difference in the primary end point for the preventive angioplasty branch . 

At the end of the study per mean of 23 months, the primary endpoint ( combined cardiac death, myocardial infarction and refractory angina ) was observed in 21 of 234 patients in the preventive angioplasty branch versus 53 of 231 patients in the control branch ( RR 0.35 , CI 0.21 to 0.58 , p < 0.001). The effect was similar in magnitude and highly significant when performing the analysis considering only cardiac death and myocardial infarction ( RR 0.36 , CI 0.18 to 0.73 , P = 0.004 ) . 

Conclusion:

In this randomized trial, we observed that  after successful primary angioplasty , perform the same procedure concomitantly of preventive angioplasty to other arteries with significant lesions but not responsible for the heart attack reduces adverse cardiovascular event risk compared with single angioplasty  limited to the responsible artery. 

Editorial Comment

This study does not answer the question about deferred angioplasty (a common practice in many centers ), where primary angioplasty is performed only in the culprit artery but in the same placement ( 48-72 hours later) completes the non culprit vessel revascularization. In this sense protocol was very rigid allowing angioplasty to other vessels in the control branch only in the context of refractory angina and ischemia determined . 

SOLACI.ORG

More articles by this author

ACC 2026 | DKCRUSH VIII: IVUS or angiography to guide PCI in complex coronary bifurcations

Intracoronary imaging guidance has become an established recommended strategy in complex coronary lesions. In the specific setting of complex bifurcations, uncertainty remained regarding the...

ACC 2026 | OPTIMAL: IVUS Guidance in PCI of the Unprotected Left Main Coronary Artery

Percutaneous coronary intervention (PCI) is considered an equivalent alternative to coronary artery bypass surgery in patients with left main coronary artery (LMCA) stenosis and...

ACC 2026 | IVUS-CHIP Trial: Intravascular ultrasound–guided versus angiography-guided complex PCI

Optimization of percutaneous coronary intervention (PCI) in complex lesions remains a relevant clinical challenge. In this context, the IVUS-CHIP trial was designed to evaluate...

ACC 2026 | ALL-RISE Trial: Coronary Physiological Assessment Using FFRangio

Coronary physiological assessment using pressure-wire techniques (FFR/iFR) carries a Class IA recommendation in ACC/AHA guidelines; however, its use remains limited due to factors such...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Management of Valve Thrombosis in TAVI: Current Evidence-Based Approach

The expansion of transcatheter aortic valve implantation (TAVI) into younger and lower-risk populations has brought bioprosthetic valve thrombosis to the forefront as a clinically...

Experience with the intra-annular self-expanding Navitor valve: data from the STS/ACC TVT registry

The expansion of TAVI, with the introduction of new-generation devices, has prioritized not only periprocedural safety, but also the preservation of coronary access, more...

Therapeutic strategies in carotid free-floating thrombus: evidence and controversies

Carotid free-floating thrombus (cFFT) is a rare entity with a high embolic risk, associated with acute neurological events such as stroke or transient ischemic...